Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer

This study has been completed.
Information provided by (Responsible Party):
Taiho Pharmaceutical Co., Ltd. Identifier:
First received: December 5, 2007
Last updated: November 1, 2012
Last verified: November 2012
The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer

Condition Intervention Phase
Colorectal Cancer
Drug: S-1, Irinotecan, Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by Taiho Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Safety [ Time Frame: any time ]

Secondary Outcome Measures:
  • Progression-free survival, Response rate, Overall survival, Treatment situation [ Time Frame: every course for first three courses, then every other course ]

Enrollment: 53
Study Start Date: October 2007
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
S-1, Irinotecan, Bevacizumab
Drug: S-1, Irinotecan, Bevacizumab

S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).

Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or metastatic disease, not amenable to curative therapy
  2. Measurable disease or non-measurable but assessable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)
  3. Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more than 180 days after the end of such treatment.
  4. Age ≥20 years
  5. Life expectancy of at least 3 months
  6. ECOG PS of 0 or 1
  7. Adequate function of major organs as defined below:

    1. Hemoglobin ≥9.0g/dL
    2. White blood cell count ≥3,500/mm3
    3. Neutrophil count ≥1,500/mm3
    4. Platelet count ≥100,000/mm3
    5. Total bilirubin ≤1.5 mg/dL
    6. AST and ALT ≤100 U/L (<200 U/L in patients with liver metastasis)
    7. Serum creatinine ≤1.2 mg/dL
    8. Creatinine clearance estimate by the Cockcroft-Gault method >50 mL/min (reduce initial dosage by one step if ≥50 but <80 mL/min)
  8. Able to take capsules orally.
  9. No electrocardiographic abnormalities within 28 days before enrollment that would clinically preclude the execution of the study, as judged by the investigator.
  10. Voluntary written informed consent.

Exclusion Criteria:

  1. Serious drug hypersensitivity or a history of drug allergy
  2. Active double cancer
  3. Active infections (e.g., patients with pyrexia of 38℃ or higher)
  4. History of gastrointestinal perforation, intestinal tract paralysis, or ileus within 1 year.
  5. Uncontrolled hypertension
  6. Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes)
  7. Moderate or severe ascites or pleural effusion requiring treatment
  8. Watery diarrhea
  9. Treatment with flucytosine or atazanavir sulfate
  10. Metastasis to the CNS
  11. Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children.
  12. Severe mental disorder
  13. Continuous treatment with steroids
  14. Urine dipstick for proteinuria should be <2+
  15. Patient with a past history of thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism
  16. Major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks
  17. Long-term daily treatment with aspirin (>325 mg/day)
  18. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
  19. Judged ineligible for participation in the study by the investigator for safety reasons.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00569790

Hokkaido University Hospital (Hokkaido Gastrointestinal Cancer Study Group)
Sapporo, Hokkaido, Japan, 060-8038
Sponsors and Collaborators
Taiho Pharmaceutical Co., Ltd.
Principal Investigator: Yoshito Komatsu Hokkaido University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Taiho Pharmaceutical Co., Ltd. Identifier: NCT00569790     History of Changes
Other Study ID Numbers: 01023018
Study First Received: December 5, 2007
Last Updated: November 1, 2012

Keywords provided by Taiho Pharmaceutical Co., Ltd.:

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017